| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99215 |
Prolong outpt/office vis |
16,562 |
15,708 |
$1.10M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,931 |
12,068 |
$528K |
| 99205 |
Prolong outpt/office vis |
2,365 |
2,354 |
$274K |
| 99223 |
Prolong inpt eval add15 m |
3,116 |
3,047 |
$269K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
12,082 |
6,606 |
$241K |
| 99233 |
Prolong inpt eval add15 m |
4,413 |
1,624 |
$205K |
| 90960 |
End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits |
1,341 |
1,339 |
$199K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
744 |
743 |
$104K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
1,985 |
841 |
$78K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
12,549 |
12,065 |
$78K |
| G9008 |
Coordinated care fee, physician coordinated care oversight services |
1,062 |
925 |
$71K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
220 |
218 |
$65K |
| 99306 |
Prolong nursin fac eval 15m |
1,026 |
999 |
$59K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
854 |
818 |
$36K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
125 |
125 |
$35K |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
2,314 |
1,905 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,481 |
4,206 |
$32K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
559 |
326 |
$29K |
| 99316 |
|
602 |
585 |
$25K |
| 90686 |
|
739 |
738 |
$22K |
| 99336 |
|
826 |
758 |
$21K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
1,072 |
931 |
$21K |
| 0011A |
|
494 |
494 |
$20K |
| G9012 |
Other specified case management service not elsewhere classified |
342 |
326 |
$18K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
57 |
57 |
$18K |
| 82607 |
|
1,349 |
1,279 |
$17K |
| 99348 |
|
1,157 |
1,067 |
$17K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
711 |
628 |
$16K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
143 |
143 |
$16K |
| 0012A |
|
346 |
346 |
$13K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
261 |
242 |
$13K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
369 |
236 |
$12K |
| 0001A |
|
273 |
273 |
$11K |
| 0002A |
|
262 |
262 |
$10K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
616 |
540 |
$9K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
197 |
194 |
$9K |
| 90656 |
|
319 |
316 |
$8K |
| 0003A |
|
220 |
220 |
$8K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
67 |
67 |
$8K |
| 90682 |
|
129 |
129 |
$8K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
40 |
40 |
$6K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
115 |
70 |
$6K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
669 |
439 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
213 |
212 |
$4K |
| 0013A |
|
84 |
84 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
27 |
27 |
$3K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
54 |
52 |
$3K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
294 |
292 |
$2K |
| 99386 |
|
17 |
17 |
$2K |
| 90694 |
|
18 |
18 |
$1K |
| 93000 |
|
40 |
40 |
$1K |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
31 |
31 |
$771.40 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
15 |
15 |
$769.65 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
47 |
46 |
$674.54 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
88 |
76 |
$527.03 |
| 0004A |
|
17 |
17 |
$500.00 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
15 |
15 |
$288.82 |
| G9920 |
Screening performed and negative |
1,553 |
1,541 |
$196.86 |
| G9919 |
Screening performed and positive and provision of recommendations |
128 |
128 |
$7.15 |
| 3078F |
|
39 |
39 |
$0.00 |
| 91300 |
|
15 |
12 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
32 |
32 |
$0.00 |
| 3075F |
|
14 |
14 |
$0.00 |
| 3074F |
|
52 |
52 |
$0.00 |
| 3044F |
|
45 |
45 |
$0.00 |
| Q0247 |
Injection, sotrovimab, 500 mg |
14 |
14 |
$0.00 |
| 3079F |
|
16 |
16 |
$0.00 |